Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-27T19:24:39.242Z Has data issue: false hasContentIssue false
  • English
  • Français

Setting new standards in schizophrenia outcomes: Symptomatic remission 3years before versus after the andreasen criteria

Published online by Cambridge University Press:  15 April 2020

P. Gorwood ,
J. Peuskens  and
on behalf of the EGOFORS initiative (European Group On Functional Outcomes, Remission in Schizophrenia)
P. Gorwood
Affiliation:
Paris Descartes university, Sainte-Anne hospital (CMME), 75014Paris, France
J. Peuskens*
Affiliation:
Paris Descartes university, Sainte-Anne hospital (CMME), 75014Paris, France
*
*Corresponding author. [email protected] (J. Peuskens).
Get access

Abstract

Symptomatic remission is often mentioned as one of the treatment goals for schizophrenia. However, the consistently with which this is documented in the schizophrenia literature since the introduction of the consensus criteria proposed by Andreasen and colleagues in 2005 has yet to be investigated. Similarly, additional treatment goals which are being discussed include improved functioning and quality of life, but whether these goals are being increasingly documented in the literature alongside symptomatic remission is as yet unknown. The objective of this article is therefore to review the use of the term ‘remission’ in the schizophrenia literature from Europe, USA and the rest of the world from 2002 to 2007, before and after the introduction of the Andreasen criteria. A second objective is to determine whether these manuscripts documenting symptomatic remission are also addressing other concepts such as functioning, quality of life and relationships. This literature review indicates that the use of the Andreasen criteria is indeed increasing, although there are manuscripts documenting alternative remission criteria or using the term remission without documentation of specific remission criteria. From 2004 to 2007 the number of manuscripts mentioning remission without documenting specific criteria has fallen by approximately 50%. Within these manuscripts there is increasing awareness of functioning and quality of life as outcome measures, in particular in manuscripts generated in Europe and the USA. This review highlights the growing importance of co-assessment of symptomatic remission and functional outcomes, and calls for further consideration of the most appropriate and consistent way to evaluate functioning of schizophrenia patients.

Keywords

SchizophreniaRemissionCriteriaFunctioningQuality of life
Type
Review
Information
European Psychiatry , Volume 27 , Issue 3 , April 2012 , pp. 170 - 175
Copyright
Copyright © Elsevier Masson SAS 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andreasen, N.C., Carpenter, W.T. Jr.Kane, J.M., Lasser, R.A., Marder, S.R., Weinberger, D.R.Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005; 162: 441–449.CrossRefGoogle ScholarPubMed
Bobes, J., Ciudad, A., Alvarez, E., San, L., Polavieja, P., Gilaberte, I.Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophr Res. 2009; 115: 58–66.CrossRefGoogle ScholarPubMed
Buckley, P.F., Harvey, P.D., Bowie, C.R., Loebel, A.The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res. 2007; 94: 99–106.CrossRefGoogle ScholarPubMed
Burns, T., Patrick, D.Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand. 2007; 116: 403–418.CrossRefGoogle ScholarPubMed
De Hert, M., van Winkel, R., Wampers, M., Kane, J., van Os, J., Peuskens, J.Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res. 2007; 92: 68–73.CrossRefGoogle Scholar
Diagnostic and statistical manual of mental disorders, Fourth edition, text revision (DSM-IV-TR) 2000, American Psychiatric Association, Arlington, VA.Google Scholar
Dunayevich, E., Sethuraman, G., Enerson, M., Taylor, C.C., Lin, D.Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res. 2006; 86: 300–308.CrossRefGoogle ScholarPubMed
Emsley, R., Rabinowitz, J., Medori, R.European Group On Functional Outcomes. Remission in Schizophrenia. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis. J Clin Psychopharm. 2008; 28: 210–213.CrossRefGoogle Scholar
Green, A.I., Lieberman, J.A., Hamer, R.M., Glick, I.D., Gur, R.E., Kahn, R.S.et al.Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006; 86: 234–243.CrossRefGoogle ScholarPubMed
Harvey, P.D., Bellack, A.S.Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?. Schizophr Bull. 2009; 35: 300–306.CrossRefGoogle Scholar
Helldin, L., Kane, J.M., Karilampi, U., Norlander, T., Archer, T.Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res. 2007; 93: 160–168.CrossRefGoogle ScholarPubMed
Leucht, S., Beitinger, R., Kissling, W.On the concept of remission in schizophrenia. Psychopharmacology. 2007; 194: 453–461.CrossRefGoogle ScholarPubMed
Leucht, S., Lasser, R.The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry. 2006; 39: 161–170.CrossRefGoogle Scholar
Lieberman, J.A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L.et al.Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs chloropromazine. Neuropsychopharmacology. 2003; 28: 995–1003.CrossRefGoogle Scholar
Llorca, P.M., Sacchetti, E., Lloyd, K., Kissling, W., Medori, R.Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. lnt J Clin Pharmacol Ther. 2008 14–22.CrossRefGoogle Scholar
Nasrallah, H.A., Lasser, R.Improving patient outcomes in schizophrenia; achieving remission. J Psychopharmacol. 2006; 20: 57–61.CrossRefGoogle ScholarPubMed
Opler, M.G., Yang, L.H., Caleo, S., Alberti, P.Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry. 2007; 7: 35.CrossRefGoogle ScholarPubMed
Remington, G., Kapur, S.Remission: what's in a Name?. Am J Psychiatry. 2005; 162: 2393–2394.CrossRefGoogle Scholar
San, L., Ciudad, A., Alvarez, E., Bobes, J., Gilaberte, I.Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry. 2007; 22: 490–498.CrossRefGoogle ScholarPubMed
Shrivastava, A., Johnston, M., Shah, N., Bureau, Y.Redefining outcome measures in schizophrenia: integrating social and clinical parameters. Curr Opin Psychiatry. 2010; 23: 120–126.CrossRefGoogle ScholarPubMed
Simonsen, E., Friis, S., Haahr, U., Johannessen, J.O., Larsen, T.K., Melle, I.et al.Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr Scand. 2007; 116: 54–61.CrossRefGoogle ScholarPubMed
van Os, J., Burns, T., Cavallaro, R., Leucht, S., Peuskens, J., Helldin, L.et al.Standarized remission criteria in schizophrenia. Acta Psychiatrica Scand. 2006; 113: 91–95.Google Scholar
van Os, J., Drukker, M., à Campo, J., Meijer, J., Bak, M., Delespaul, P.Validation of remission criteria for schizophrenia. Am J Psychiatry. 2006; 163: 2000–2002.CrossRefGoogle Scholar
Wunderink, L., Sytema, S., Nienhuis, F.J., Wiersma, D.Clinical recovery in first-episode psychosis. Schizophr Bull. 2009; 35: 362–369.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.